BRAF and melanoma: In a pivotal phase III randomised trial in patients with BRAF-mutant melanoma, vemurafenib achieved an objective response rate of 48% and median PFS of 5.3 months versus 5% and 1.6 months with dacarbazine, respectively (Chapman et al, 2011; Kudchadkar et al, 2013).